Clinical Research Directory

Inclusion Criteria * Both males and females will be enrolled and must be at least 18 years of age under age of 90 * Patients who, in the opinion of the Investigator, are at elevated risk of developing a pancreatic malignancy because they have known risk factors for PDAC. * High risk asymptomatic patients being screened for PDAC. * All patients must undergo contemporaneous imaging (within 90 days of LINFU®) with one or more of the following: EUS± FNA, MRI/MRCP, ERCP, CT or CEUS. * Institutional Review Board (IRB)-approved consent must be signed by patients to participate in this study. Exclusion Criteria: * Patient under the age of 18 and over the age 90 * Contraindications to LINFU®/EUS/ERCP as determined by study investigators including: patient with uncorrectable coagulopathy; patient that cannot undergo anesthesia due to cardiopulmonary contraindication as deemed by the anesthesiologist; unstable medically (cardiopulmonary, neurologic, or cardiovascular status) * Patients with clinical signs or symptoms of PDAC * Patients undergoing EUS or ERCP for a suspected bile duct cancer arising from the intrahepatic or extrahepatic biliary epithelium * Patients with documented intraductal papillary mucinous neoplasm of the pancreas (IPMN) * Pregnant females will be excluded * Patient that is unable to provide informed consent * Patient with known allergy to the microbubble contrast agent or secretin